Home Archive Blogs Collections Podcasts Videos Info & Services
Skip Navigation LinksHome > September 25, 2013 - Volume 35 - Issue 18 > iPad Extra: Next Steps for Sorafenib in RAI-Refractory DTC
Oncology Times:
doi: 10.1097/01.COT.0000435377.89374.6f
News

iPad Extra: Next Steps for Sorafenib in RAI-Refractory DTC

Free Access
Figure
Image Tools

Get the iPad edition of this issue to listen to additional key thyroid cancer news from the ASCO Annual Meeting. Download the Sept. 25 FOCUS: Thyroid Cancer Supplement iPad issue to hear OT reporter Dan Keller's video interview with:

Marcia S. Brose, MD, PhD, Assistant Professor of Otolaryngology and Head and Neck Surgery at Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania, who discusses the results of the DECISION trial and the next steps of the research. The data, reported at the Plenary Session, showed that the multi-targeted drug sorafenib extends progression-free survival for patients with differentiated thyroid cancer that is resistant to standard radioiodine therapy—making it the first drug to demonstrate efficacy of any agent for this type of thyroid cancer.

Figure
Image Tools
Figure
Image Tools

To receive our iPad issues, download the free Oncology Times app from the App Store fromhttp://bit.ly/OT-iPadApp, search in the App Store, or follow the link ononcology-times.com.

Wolters Kluwer Health | Lippincott Williams & Wilkins

Login

Article Tools

Images

Share